Transcept Pharmaceuticals Inc (TSPT)

[the_breeze]

Here's a little info on their pipeline drug..see website for more:

About TO-2061

Transcept is developing TO-2061, a low dose form of ondansetron, as an adjunctive therapy in patients with obsessive compulsive disorder (OCD) who have not adequately responded to approved first-line therapy. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families. Approximately 50 percent of patients do not respond adequately to standard first-line treatment with approved OCD medications, including the selective serotonin re-uptake inhibitors (SSRIs) and the tricyclic agent, clomipramine. There is no FDA approved augmentation therapy for these treatment resistant patients.